Opthea Limited (OPT.AX)

0,6300 +0,0050 (+0,80%) Alla chiusura: 03:59PM AEST

Opthea Limited

650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
https://opthea.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 24

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.	Founder, Chief Innovation Officer & Executive Director	910,2k	N/D	1975
Ms. Judith J. Robertson B.A., M.B.A.	Chief Commercial Officer	893,29k	N/D	1961
Ms. Karen Adams CPA	VP of Finance & Company Secretary	463,11k	N/D	1972
Dr. Frederic Guerard M.S., Pharm.D.	Chief Executive Officer	N/D	N/D	1973
Mr. Peter F. Lang M.B.A.	Chief Financial Officer	N/D	N/D	1973
Ms. Sarika Gulhar Ph.D.	Executive Director of Human Resources	N/D	N/D	N/D
Dr. Michael Gerometta Ph.D.	Head of Chemistry, Manufacturing & Controls Development	199,09k	N/D	1965
Mr. Bruno Gagnon BPHARM, M.Sc.	Senior Vice President of Global Clinical Operations	N/D	N/D	1969
Dr. Kenneth Sall	Chief Medical Officer	N/D	N/D	N/D
Dr. Fang Li Ph.D.	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in AUD.

Descrizione

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Governance aziendale

L'ISS Governance QualityScore di Opthea Limited al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 6; diritti degli azionisti: 10; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.